The effectiveness of conservative treatment of patients with age-related degeneration of the macula and posterior pole with the drug Slezavit

Authors: N. V. Konovalova, MD, N. I. Khramenko, PhD, O. V. Guzun, PhD

State Institution «Institute of Eye Diseases and Tissue Therapy named after . V. P. Filatov NAMS of Ukraine», Odessa


The presented study analyzed morphometric and functional changes in the visual analyzer in a group of patients with VMD with a relatively early identified process and fairly high visual functions. With a slightly pronounced violation of the architectonics, according to OCT data, the activity of primarily the photopic afferent system as the most sensitive component of the visual analyzer, which reacts sharply to all kinds of trophic disturbances, noticeably decreases.

Complex treatment, including anti-ischemic, antioxidant and vitamin agents, is pathogenetically targeted, improving retinal trophism. The inclusion of drugs with lutein and zeaxanthin in the complex treatment of patients with degeneration of the macula and posterior pole has a positive effect on the functional state of the retina.

The purpose of our study was to determine the effectiveness of conservative treatment and stabilization of visual functions in patients with macular and posterior pole degeneration who received the drug Slezavit.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design